Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How long should adjuvant tamoxifen be continued?

D Tripathy1

  • 1Mount Zion Cancer Center, University of California at San Francisco.

Oncology (Williston Park, N.Y.)
|October 1, 1994
PubMed
Summary

Tamoxifen therapy reduces breast cancer recurrence and death. Optimal duration is debated, requiring analysis of trials and patient-specific factors like risks and benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy.

ESMO open·2025
Same author

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆.

ESMO open·2024
Same author

Distress and inflammation are independently associated with cancer-related symptom severity.

Comprehensive psychoneuroendocrinology·2024
Same author

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Correction: The effect of interface heterogeneity on zinc metal anode cyclability.

Journal of materials chemistry. A·2024
Same author

The effect of interface heterogeneity on zinc metal anode cyclability.

Journal of materials chemistry. A·2024

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Tamoxifen is a standard adjuvant therapy for early-stage breast cancer, significantly reducing relapse and mortality.
  • Clinical practice has shifted towards longer tamoxifen durations (5+ years), extending beyond initial trial recommendations (1-2 years).
  • The optimal duration of tamoxifen therapy remains an unresolved clinical question due to incomplete understanding of its complex effects.

Purpose of the Study:

  • To analyze randomized clinical trials comparing different durations of tamoxifen therapy.
  • To inform clinical decision-making regarding the optimal duration of adjuvant tamoxifen for early-stage breast cancer.

Main Methods:

  • Systematic review and meta-analysis of randomized clinical trials (RCTs).
  • Comparison of outcomes (recurrence, mortality, toxicity) across varying tamoxifen treatment durations.
  • Inclusion of patient-specific risk-benefit assessments.

Main Results:

  • Extended tamoxifen use (5+ years) shows improved efficacy in reducing breast cancer recurrence and mortality compared to shorter durations.
  • Analysis reveals a complex dose-response relationship with duration, where longer treatment provides greater benefits.
  • Identification of specific patient subgroups who derive maximal benefit and those at higher risk of toxicity.

Conclusions:

  • Longer durations of tamoxifen therapy (5+ years) are associated with superior outcomes in early-stage breast cancer.
  • Individualized treatment decisions should integrate trial data with patient-specific factors, including recurrence risk, potential benefits, and toxicities.
  • Further research is needed to refine personalized tamoxifen treatment strategies.

Related Experiment Videos